Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology
October 26 2016 - 2:31AM
Lund (Sweden) and Tel Aviv
(Israel), 26 October 2016 - Active Biotech AB (NASDAQ OMX
NORDIC: ACTI) and NeoTX Therapeutics Ltd. announced today that they
have entered into a licensing agreement for Active Biotech's
investigational compound Naptomumab estafenatox ("ANYARA") for
cancer immunotherapy. NeoTX will be responsible for the
worldwide clinical development and commercialization of the
drug. This partnership is a key milestone in NeoTX's strategy
to bring tumor recognition enhancing therapeutics to the
market.
"We are very enthusiastic about our collaboration
with Active Biotech. At NeoTX, we are strongly committed to
developing innovative immunotherapies for unmet medical needs.
"Active Biotech brings to our collaboration outstanding scientific
and intellectual capital, and a powerful commitment to positively
impact the treatment of cancer," said Asher
Nathan, Chief Executive Officer of NeoTX.
Dr. Marcel Rozencweig, Chief Medical Officer of
NeoTX and former Head of Global Clinical Oncology Research at
BMS said "We are looking forward to developing
ANYARA for immuno-oncology applications. We believe that the ANYARA
technology is well suited to increase tumor recognition by the
immune system and has demonstrated synergistic activity in
combination with checkpoint inhibitors in animal models. As such,
ANYARA would be attractive in combination with checkpoint
inhibitors whose efficacy can be limited by poor tumor
recognition".
"We are excited about the partnership with NeoTX,
who we consider as an ideal partner for ANYARA. This partnership
constitutes the next step in the clinical development, as well as
the commercialization strategy, for the project." said
Tomas Leanderson, President & CEO of
Active Biotech.
About the agreement
Under the terms of the agreement, Active Biotech grants NeoTX
exclusive rights to develop and commercialize ANYARA worldwide in
cancer indications. The total deal value amounts to $71 million and
is contingent upon achievement of clinical, regulatory and
commercial milestones whereof Active Biotech will receive $250 000
as an initial payment upon signing. In addition, NeoTX will
pay Active Biotech progressive, double-digit royalties on its net
sales.
About ANYARA
ANYARA is a TTS (Tumor Targeting Superantigen) compound that
increases the ability of the immune system to recognize the tumor.
Synergy has been reported in vivo with a combination of ANYARA and
a checkpoint inhibitor in an experimental tumor model. Clinically,
the development of ANYARA has primarily been focused on cancer
indications with a high unmet medical need. Positive data was
reported from clinical Phase I trials in lung cancer, renal cell
cancer and pancreatic cancer, where ANYARA was studied both as a
single agent (monotherapy) and in combination with an established
tumor therapy - docetaxel (Taxotere®) - in patients with advanced
cancer. The results showed that ANYARA was well tolerated both as
monotherapy and in combination with docetaxel, and increased tumor
recognition by T cells.
A Phase 2/3 trial of ANYARA in combination with interferon alpha in
renal cell cancer demonstrated acceptable safety but did not meet
its primary efficacy endpoint in the ITT population. The upcoming
clinical trial will be done in combination with drugs that inhibit
checkpoint dampening of the immune system, a combination strategy
in line with the mode of action of ANYARA and supported by
preclinical data.
NeoTX Therapeutics Ltd. is
based in Rehovot Israel and is a clinical stage immuno-oncology
company. NeoTX was founded to bring safe and effective
immunotherapies to cancer patients. Please visit www.neotx.com for
more information.
Active Biotech AB (publ) (Nasdaq Stockholm:
ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in pivotal Phase 3 development for the treatment of
relapsing remitting multiple sclerosis. Also, laquinimod is in
Phase 2 development for the treatment of primary progressive
multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, paquinimod
and SILC projects. Please visit www.activebiotech.com for more
information.
For further information, please contact:
Asher Nathan CEO
Tel: +1 609 718 2305 x 1
Robert Harow, CFO
Tel: +1 609 718 2305 x 2 |
NeoTX Therapeutics Ltd.
(Corp.Reg. No. 515220929)
2 Pekeris Street
Rehovot, Israel
Tel: +1 609 718 2305
Tel: +972 3 912 5853
|
Tomas
Leanderson, President and CEO
Tel: +46 46 19 20 95
Hans Kolam, CFO
Tel: +46 46 19 20 44 |
Active
Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 46 19 20 00
|
This information is information that Active Biotech AB is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency
of the contact person set out above, at 08.30 am CET on October 26,
2016.
20161026_Active
Biotech_NeoTX_
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024